Technology
Health
Pharmaceutical
Avenue Therapeutics
$4.749876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$4.74
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.04 (-0.91%) Today
-$0.01 (-0.14%) After Hours
Why Robinhood?
You can buy or sell ATXI and other stocks, options, ETFs, and crypto commission-free!
About
Avenue Therapeutics, Inc. engages in acquiring, licensing, developing, and commercializing products for use in the intensive care hospital setting. It focuses on the development of intravenous tramadol, which is intended for the treatment of moderate to moderately severe post-operative pain. Read More The company was founded on February 9, 2015 and is headquartered in New York, NY.
CEO
Employees
6
Headquarters
New York, New York
Founded
2015
Market Cap
78.59M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
48.19K
High Today
$4.77
Low Today
$4.68
Open Price
$4.77
Volume
12.40K
52 Week High
$6.82
52 Week Low
$2.08
Collections
Technology
Health
Pharmaceutical
Therapy
2017 IPO
US
North America
Female CEOs
News
Yahoo FinanceMay 13
Avenue Therapeutics Reports First Quarter 2019 Financial Results and Recent Corporate Highlights
Safety study completed; Expect to report data from 2nd pivotal Phase 3 trial by the end of second quarter 2019 NEW YORK, May 13, 2019 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today reported financial results and recent corporate highlights for the first quarter ended March 31, 2019. “We recently completed the safety study for IV tramadol and expect to report data by the end of this quarter fr...
Guru FocusApr 30
Avenue Therapeutics Announces Appointment of Dr. Thomas G. Moore to Board of Directors
NEW YORK, April 30, 2019 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. ( ATXI) (“Avenue”), a specialty pharmaceutical company focused on the development and commercialization of intravenous (IV) tramadol, today announced that Dr. Thomas G. Moore has been appointed to its Board of Directors. “Tom’s breadth and depth of operational and commercial experience, which includes leadership in the acute care pharmaceutical business, will be a significant asset to Avenue,” said Dr. Lindsay Rosenwald, Avenue’s Exec...
Price Paid on Robinhood
7% Lower
Right Now
52 Week Low
$2.08
Average Price Paid
$5.08
52 Week High
$6.82
Earnings
-$1.03
-$0.77
-$0.51
-$0.25
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
-$0.43 per share
Actual
-$0.82 per share